No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...

The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.

Roche’s phase III MUSETTE trial of Ocrevus high dose in people with relapsing multiple sclerosis fails to meet primary endpoint: Basel Friday, April 4, 2025, 11:00 Hrs [IST] Roc ...

Roche's Ocrevus trial fails to meet expectations, causing stock drop despite positive safety results for higher dose.

RHHBY's higher dose of multiple sclerosis drug Ocrevus did not meet its primary goal when compared to the approved 600 mg dose in relapsing multiple sclerosis patients.

Higher doses of the company’s intravenously delivered multiple sclerosis drug failed to show additional benefit in slowing ...

BofA analyst Alec Stranahan raised the firm’s price target on TG Therapeutics (TGTX) to $11 from $10 and keeps an Underperform rating on the ...

Swiss pharma major Roche (ROG: SIX) said a higher-dose version of its top-selling multiple sclerosis drug Ocrevus ...

Pharmaceutical stocks saw strong gains on Thursday after US President Donald Trump announced that pharmaceuticals would be ...

Cellares' cell therapy factory-in-a-box scores coveted advanced manufacturing technology tag from FDA (fiercepharma.com) — ...

(Bloomberg) -- Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the original in a large study, potentially reducing the drugmaker’s ...

“These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow disability progression,” ...